ACE2 and COVID-19: The receptor‐binding domain (RBD) of the spike protein that coats the surface of SARS‐CoV‐2 is an appealing target antigen for COVID‐19 subunit vaccines.[4] RBD is the portion of the spike that binds to the human angiotensin converting enzyme 2 (ACE2) receptor to mediate viral infection.